BioSpace News Archive

Novo Nordisk today presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease (CKD), at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA).

Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of John Maraganore, Ph.D., as a Strategic Advisor and Board Observer.

Healcisio, a leader in AI and digital healthcare, announces it has received a $1 Million STTR Phase II award from the NIAID to advance the development of its critical care decision support platform and a new AI-powered software suite for abstracting and reporting quality measures.

Douglas Pharmaceuticals, New Zealand’s largest pharmaceutical company, is pleased to announce that results from their recent trial, “Randomised Placebo-Controlled Phase 2 Study of Extended-Release Ketamine Tablets (R-107) for Treatment-Resistant Depression”, also known as the BEDROC study, have just been published by the leading scientific journal Nature Medicine.

A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc., a leader in genetic testing and precision medicine.

Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO®.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association’s 84th Scientific Sessions.

GRAIL, Inc. announced its spin-off from Illumina is complete, and GRAIL will be listed and commence regular-way trading on the Nasdaq under the symbol “GRAL” as of tomorrow, June 25, 2024.

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) today announced its financial results for the fiscal fourth quarter and year ended March 31, 2024, and provided a corporate update.